The hypertensive effects of the renin-angiotensin

Size: px
Start display at page:

Download "The hypertensive effects of the renin-angiotensin"

Transcription

1 Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point trial compared telmisartan and valsartan for treating mild to moderate hypertension. Efficacy for 24-hour control of blood pressure was assessed using ambulatory blood pressure monitoring. Mean changes in diastolic blood pressure for the last 6 hours before dosing and the nighttime period were significantly greater with telmisartan than with valsartan (p<0.01 for the last 6 hours before dosing; p<0.05 for the nighttime period). Mean changes in systolic and diastolic blood pressures for the 24-hour interval, the morning, and the daytime periods were significantly greater with telmisartan than with valsartan (p<0.01). The incidence of all adverse events and the most common adverse events were comparable for patients receiving telmisartan and patients receiving valsartan. Neither treatment was associated with cough. These data suggest greater efficacy for telmisartan than valsartan in controlling blood pressure throughout the 24-hour dosing interval, including the last 6 hours before dosing, and the two agents were similarly well tolerated. (J Clin Hypertens. 2002;4:26 31) 2002 Le Jacq Communications, Inc. From the Department of Preventive Medicine and Internal Medicine, Rush Hypertension/Clinical Research Center, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL Address for correspondence: George Bakris, MD, 1700 W. Van Buren Street, Suite 470, Chicago, IL Manuscript received January 23, 2002; accepted February 26, 2002 The hypertensive effects of the renin-angiotensin system (RAS) are mediated by the binding of angiotensin II to the angiotensin type 1 (AT 1 ) receptor. Several antagonists of the AT 1 receptor have been developed for clinical use, including telmisartan, valsartan, losartan, eprosartan, irbesartan, and candesartan; these compounds are highly effective and generally well tolerated antihypertensive agents. 1 3 However, the AT 1 receptor antagonists differ in their pharmacokinetic properties. The angiotensin II receptor blocker (ARB) telmisartan has pharmacokinetic properties that suggest it has a duration of action sufficient for once-daily dosing, with a T max 1 hour and a T 1/2 of 24 hours. In contrast, losartan, which was the first ARB to be developed, has a T max of 3 4 hours and a T 1/2 of 6 9 hours, and valsartan, another ARB, has a T max of 2 4 hours and a T 1/2 of 6 hours. 4 However, receptor binding of these compounds may go beyond their measured half-lives. The most accurate way to measure the duration of action of an antihypertensive agent is to use ambulatory blood pressure monitoring (ABPM). 5 7 ABPM has other advantages compared with traditional cuff blood pressure measurements performed in a single clinic visit, such as greater reproducibility of data and the ability to rule out white coat hypertension. Furthermore, 24-hour ABPM data have greater clinical relevance compared with cuff measurements because this technique has been shown to more accurately predict the risk for target organ damage and cardiovascular events ABPM was used in a recent study published by Littlejohn et al. 12 that compared the efficacy of telmisartan and valsartan in the treatment of mild to 26 THE JOURNAL OF CLINICAL HYPERTENSION SUPPLEMENT 1 VOL. IV NO. IV JULY/AUGUST 2002

2 moderate hypertension. This study tested the hypothesis that telmisartan and valsartan, which have different pharmacokinetic properties, also differ in their efficacy for controlling blood pressure throughout the 24-hour dosing interval. The results of this study will be reviewed here. METHODS Adult patients with mild to moderate hypertension, defined as sitting diastolic blood pressure (DBP) of mm Hg, sitting systolic blood pressure (SBP) of mm Hg, and 24-hour mean SBP/DBP >130/85 mm Hg (determined using ABPM), and without significant metabolic or cardiovascular disease were enrolled in a prospective, randomized, open-label, blinded-end point (PROBE) study that compared the efficacy and tolerability of telmisartan 80 mg q.d. vs. valsartan 80 mg q.d. The study consisted of a 4-week placebo run-in period and an 8- week treatment period. Baseline measurements were taken at the end of the placebo run-in. Investigators were blinded to the end points. The main efficacy end points were the changes from baseline in SBP and DBP during the last 6 hours of the 24-hour dosing interval (midnight to 6 a.m.), as measured with ABPM. Other efficacy outcomes assessed with ABPM included the changes in SBP and DBP during the morning period (6 a.m. to noon), the daytime period (6 a.m. to 10 p.m.), the nighttime period (10 p.m. to 6 a.m.), and the entire 24-hour period. Changes in sitting trough SBP and DBP (from cuff measurements), and the proportion of SBP responders (patients achieving a 10 mm Hg reduction in mean 24-hour SBP) and DBP responders (patients achieving both a 10 mm Hg reduction in mean 24-hour DBP and a mean 24-hour DBP of <80 mm Hg) were also assessed by ABPM. Safety outcomes included adverse events and changes in the results of physical examinations, laboratory tests, and 12-lead electrocardiograms. Data analysis was performed by individuals blinded to patients treatment. This study was approved by institutional review boards at participating centers, and all patients provided written informed consent. RESULTS A total of 214 patients were randomized to receive telmisartan 80 mg, and 212 patients were randomized to receive valsartan 80 mg. The treatment groups were similar with respect to age, sex, race, and history and severity of hypertension (Table I). The mean age of patients in the study was 53.3 years, and most of the patients (85.7%) were aged <65 years. More than one half were male (68.1%), and most were white (83.3%). The mean duration of hypertension was 10.2 years (median, 7.5 years). Mean 24-hour SBP/DBP at baseline was 151.4/93.8 mm Hg, and the trough cuff SBP/DBP at baseline was 157.1/100.8 mm Hg (Table II). Mean changes in DBP and SBP for the last 6 hours before dosing and the nighttime period were greater for the telmisartan group than for the valsartan group (Figures 1 and 2), and the differences Table I. Patient Demographics (N=214) ALL (N=426) Mean age, years (SD) 53.6 (10.4) 53.1 (9.6) 53.3 (10.0) Age group, n (%) Sex, n (%) Race, n (%) <65 Years 183 (85.5) 182 (85.8) 365 (85.7) 65 Years 31 (14.5) 30 (14.2) 61 (14.3) Men 146 (68.2) 144 (67.9) 290 (68.1) Women 68 (31.8) 68 (32.1) 136 (31.9) White 179 (83.6) 176 (83.0) 355 (83.3) Black 31 (14.5) 33 (15.6) 64 (15.0) Asian 4 (1.9) 3 (1.4) 7 (1.6) Duration of hypertension, years Mean Median Adapted with permission from Can J Cardiol. 2000;16: SUPPLEMENT 1 VOL. IV NO. IV JULY/AUGUST 2002 THE JOURNAL OF CLINICAL HYPERTENSION 27

3 Table II. Mean Blood Pressure and Pulse Rate at Baseline 24-Hour ABPM Seated trough cuff ALL N SBP, mm Hg (12.4) (12.3) (12.3) DBP, mm Hg 93.3 (6.1) 94.3 (6.4) 93.8 (6.3) Pulse rate, bpm 78.8 (9.4) 78.8 (9.4) 78.8 (9.4) N SBP, mm Hg (12.9) (12.4) (12.6) DBP, mm Hg (4.9) (5.1) (5.0) Pulse rate, bpm 74.9 (8.2) 74.4 (9.0) 74.7 (8.6) Values are means±sd. ABPM=ambulatory blood pressure monitoring; bpm=beats per minute; DBP=diastolic blood pressure; SBP=systolic blood pressure; Reproduced with permission from Can J Cardiol. 2000;16: between the groups in mean changes in DBP were significant (p<0.01 for the last 6 hours before dosing; p<0.05 for the nighttime period; Figure 1). Mean changes in SBP and DBP for the 24-hour interval, the morning, and the daytime periods were significantly greater for the telmisartan group than for the valsartan group (p<0.01; Figures 1 and 2). The 24-hour blood pressure profiles showed that treatment with telmisartan was associated with greater mean changes in hourly SBP and DBP over the 24-hour dosing interval for almost all time points, compared with valsartan (Figures 3 and 4). Mean decreases in sitting trough SBP and DBP were significantly greater for patients receiving telmisartan than for patients receiving valsartan (p<0.01 for SBP; p=0.01 for DBP; Table III). The proportion of SBP treatment responders was significantly greater in the telmisartan group than in the valsartan group (p<0.01), and the proportion of DBP treatment responders was numerically greater for the telmisartan group relative to the valsartan group (Table IV). The safety outcomes for the telmisartan and valsartan groups were similar. Most adverse events were mild to moderate in nature. The incidence of all adverse events for patients receiving telmisartan (44.4%) and patients receiving valsartan (44.3%) was comparable, the incidence of the most common Figure 1. Adjusted* mean changes from baseline (±SEM) in systolic blood pressure, determined by ambulatory blood pressure monitoring. Morning=6 a.m. 11:59 a.m.; daytime=6 a.m. 9:59 p.m.; nighttime=10 p.m. 5:59 a.m.; last 6 hours refers to time before dosing. *Adjusted for the main effect of center and using baseline as a covariate; p <0.01 vs. valsartan. 12 Figure 2. Adjusted* mean changes from baseline (±SEM) in diastolic blood pressure determined by ambulatory blood pressure monitoring. Morning=6 a.m. 11:59 a.m.; daytime=6 a.m. 9:59 p.m.; nighttime=10 p.m. 5:59 a.m.; last 6 hours refers to time before dosing. *Adjusted for the main effect of center and using baseline as a covariate; p<0.01 vs. valsartan; p<0.05 vs. valsartan THE JOURNAL OF CLINICAL HYPERTENSION SUPPLEMENT 1 VOL. IV NO. IV JULY/AUGUST 2002

4 Figure 3. Mean change from baseline in mean hourly systolic blood pressure, determined by ambulatory blood pressure monitoring. Dosing occurred during the morning; hours 1 6 relative to dosing correspond to approximately 6:00 a.m. to noon. Figure 4. Mean change from baseline in mean hourly diastolic blood pressure, determined by ambulatory blood pressure monitoring. Dosing occurred during the morning; hours 1 6 relative to dosing correspond to approximately 6:00 a.m. to noon. adverse events was similar for the two treatment groups, and neither treatment was associated with cough (Table V). DISCUSSION In a study reported by Littlejohn et al., 12 the efficacy and tolerability of telmisartan 80 mg and valsartan 80 mg for controlling blood pressure throughout the 24-hour dosing interval were directly compared. One limitation in interpreting these data is that since the usual starting doses are 80 mg/d for valsartan and 40 mg/d for telmisartan, the doses compared here are not necessarily equivalent. However, other studies have used the 80-mg dose, so for the purposes of comparison to other studies this dose is appropriate. Mean changes in DBP for the last 6 hours before dosing and the nighttime period were significantly greater for the telmisartan group than for the valsartan group, and the mean changes in SBP for those time periods were numerically greater for the telmisartan group. Mean changes in 24-hour, morning, and daytime SBP and DBP were significantly greater in the telmisartan group relative to the valsartan group. The 24-hour blood pressure profiles showed that telmisartan treatment was associated with greater mean decreases in hourly blood pressure at almost every time point, compared with valsartan treatment; differences in outcomes between the two treatment groups were greatest during the daytime hours. The PROBE design for clinical trials, used in this study, has some advantages over the randomized, double-blind, placebo-controlled trial design. These advantages include lower cost; less time required for completion, treatment, and follow-up; administration in an open manner, similar to that of treatment in the community setting; and the ability to recruit patients who would not be eligible for enrollment in a placebo-controlled study. 13 Investiga- Table III. Mean Change From Baseline in Trough Cuff Blood Pressure P VALUE SBP, mm Hg 13.5 (0.9) 9.7 (0.9) <0.01 DBP, mm Hg 8.9 (0.5) 7.1 (0.5) 0.01 Values are means±sem. DBP=diastolic blood pressure; SBP=systolic blood pressure Table IV. Blood Pressure Response Rates (N=199) (N=197) P VALUE SBP response,* % of patients <0.01 DBP response, % of patients DBP=diastolic blood pressure; SBP=systolic blood pressure; *defined as a reduction from baseline in the mean 24-hour SBP of 10 mm Hg; defined as a mean 24-hour DBP of <80 mm Hg or a reduction from baseline of 10 mm Hg SUPPLEMENT 1 VOL. IV NO. IV JULY/AUGUST 2002 THE JOURNAL OF CLINICAL HYPERTENSION 29

5 Table V. Treatment-Emergent Adverse Events With Incidence 2% ADVERSE EVENT, N (%) (N=214) Headache 22 (10.3) 22 (10.4) Upper respiratory tract infection 15 (7.0) 13 (6.1) Accident, household 4 (1.9) 8 (3.8) Dizziness 6 (2.8) 7 (3.3) Fatigue 4 (1.9) 6 (2.8) Pain 2 (0.9) 6 (2.8) Pharyngitis 5 (2.3) 5 (2.4) Sinusitis 5 (2.3) 5 (2.4) Back pain 5 (2.3) 1 (0.5) Reproduced with permission from Can J Cardiol. 2000;16: tor bias is avoided by blinding the investigators to the end points and by having individuals who are blinded to patients treatment assignments analyze the data. In the telmisartan vs. valsartan PROBE study, ambulatory blood pressure findings constituted the blinded end point. A complete evaluation of the efficacy of an antihypertensive agent includes assessment of 24-hour blood pressure control. Most antihypertensive medications are taken once daily, which is preferable to more frequent dosing because of greater patient compliance with once-daily dosing. 14 Dosing is commonly performed during the morning to provide blood pressure control during the daytime hours, when blood pressure would reach its highest levels. However, morning administration may result in very low plasma drug concentrations throughout the last several hours before dosing and the first few hours after dosing, which are hours that coincide with a circadian increase in blood pressure that is believed to contribute to the heightened risk for cardiovascular and cerebrovascular events observed for this time period The efficacy of telmisartan for controlling blood pressure over the 24-hour dosing interval also has been shown to be significantly greater than that of another ARB, losartan, as well as that of amlodipine, a calcium channel blocker. Treatment with telmisartan resulted in significantly greater mean decreases in SBP and DBP during the last 6 hours before dosing, compared with losartan treatment. 7 Similarly, telmisartan was associated with significantly greater mean decreases in SBP and DBP during the last 6 hours before dosing, compared with amlodipine. 6 The significant efficacy findings of the studies comparing telmisartan with valsartan, losartan, and amlodipine indicate that telmisartan is highly effective during the early morning hours before dosing, which coincide with the greatest cardiovascular risk during the day. In addition, clinical studies have shown the efficacy of telmisartan for treatment of mild to moderate hypertension to be similar to that of the angiotensinconverting enzyme (ACE) inhibitors enalapril and lisinopril and similar to that of enalapril for the treatment of severe hypertension These findings are in contrast to a common misperception that the ACE inhibitors, which are older drugs and therefore have a larger body of clinical data, are more effective than the ARBs. Although the ARBs and the ACE inhibitors have shown similar efficacy for lowering blood pressure in clinical trials, there are more data on cardiovascular morbidity and mortality for ACE inhibitor treatment than for therapy with ARBs. However, key outcome data on telmisartan should be provided by the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET), which will enroll more than 23,400 patients with cardiovascular disease, peripheral vascular disease, or diabetes mellitus along with target organ damage and follow them for up to 5.5 years. The ONTARGET study will compare the effects of telmisartan, ramipril, and telmisartan plus ramipril combination therapy on a combined end point consisting of cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. 22 Treatment with such ARBs as telmisartan, unlike ACE inhibitor therapy, has not been associated with cough. 4 The excellent tolerability associated with ARBs is consistent with their specific mechanism of action via the AT 1 receptor, and a lack of interaction with the kallikrein-kinin pathway, which has been linked to ACE inhibitor-induced 30 THE JOURNAL OF CLINICAL HYPERTENSION SUPPLEMENT 1 VOL. IV NO. IV JULY/AUGUST 2002

6 cough In this study, treatment with telmisartan and valsartan was similarly well tolerated, and the adverse event profiles for these agents were comparable to those seen in other studies. 5 7 Therapy with ARBs has been recommended for patients who do not tolerate ACE inhibitor treatment because ARBs are better tolerated and limited data suggest that ARB treatment may confer similar survival benefits. The Telmisartan Randomized Assessment Study in ACE Inhibitor-Intolerant Patients With Cardiovascular Disease (TRANSCEND) will provide outcome data for telmisartan treatment in patients with cardiovascular disease who are intolerant of ACE inhibitor therapy. The TRANSCEND study will enroll 5000 patients and will have the same end points as ONTARGET. 22 The results of the study reported here demonstrate greater efficacy for telmisartan than for valsartan in controlling blood pressure throughout the 24-hour dosing interval, including the last 6 hours before dosing. Both agents were well tolerated and most adverse events were mild to moderate in severity. REFERENCES 1 Oliverio MI, Coffman TM. Angiotensin-II receptors: new targets for antihypertensive therapy. Clin Cardiol. 1997;20: Weber MA. Comparison of type 1 angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors in the treatment of hypertension. J Hypertens. 1997;15(suppl): S31 S36. 3 Drincic V, Koshy S, Bakris G. Angiotensin receptor blocker use for hypertension treatment in the elderly. Ann Long-Term Care. 1999;7: Bakris GL, Giles TD, Weber MA. Clinical efficacy and safety profiles of AT 1 receptor antagonists. Cardiovasc Rev Reports. 1999;20(2): Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther. 1997;19: Lacourcière Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit. 1998;3: Mallion JM, Siché JP, Lacourcière Y, and the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mildto-moderate hypertension. J Hum Hypertens. 1999; 13: Neutel JM, Smith DH, Weber MA. What are the approaches for evaluating antihypertensive treatment by 24-h ambulatory blood pressure monitoring? Blood Press Monit. 1999;4(suppl 2):S23 S28. 9 Pickering TG, Coats A, Mallion JM, et al. Blood Pressure Monitoring. Task Force V: White-coat hypertension. Blood Press Monit. 1999;4: Waeber B, Brunner HR. Clinical value of ambulatory blood pressure monitoring in the assessment of antihypertensive therapy. Blood Press Monit. 1999;4: White WB. Ambulatory blood pressure as a predictor of target organ disease and outcome in the hypertensive patient. Blood Press Monit. 1999;4: Littlejohn T, Mroczek W, Marbury T, et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 2000;16: Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1: National Heart, Lung, and Blood Institute. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Washington, DC: National Institutes of Health; Publication NIH Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313(21): Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. Circulation. 1987;75: Cooke HM, Lynch A. Biorhythms and chronotherapy in cardiovascular disease. Am J Hosp Pharm. 1994;51: Cooke-Ariel H. Circadian variations in cardiovascular function and their relation to the occurrence and timing of cardiac events. Am J Health Syst Pharm. 1998;55(suppl 3):S5 S Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999;17: Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999;6: Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract. 1999;53: Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol. 2002;89(2A):18A 26A. 23 Fuller RW, Dixon CM, Cuss FM, et al. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis. 1987;135: Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;329: Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med. 1996;156: SUPPLEMENT 1 VOL. IV NO. IV JULY/AUGUST 2002 THE JOURNAL OF CLINICAL HYPERTENSION 31

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension (2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers

More information

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs (2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal

More information

Angiotensin II receptor blockers (ARBs) are the

Angiotensin II receptor blockers (ARBs) are the Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Suzanne Oparil, MD; 1 David Williams, MD; 2 Steven G. Chrysant, MD, PhD; 3 Thomas C. Marbury,

More information

A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours

A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours REVIEW A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours Philippe Gosse Service de Cardiologie Hypertension artérielle, Hôpital Saint André, Bordeaux

More information

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN

More information

Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension*

Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension* The Journal of International Medical Research 2005; 33 (Suppl 1): 21A 29A Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with

More information

AT 1 -receptor blockers: differences that matter

AT 1 -receptor blockers: differences that matter (2002) 16, S9 S16 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh AT 1 -receptor blockers: differences that matter Division of Cardiovascular Diseases, The Western

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:

More information

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent

More information

Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Done by :Meznah zaid Al-mutairi Pharm.D Candidate Princess Nora Bint Abdul Rahman University

More information

The Journal of International Medical Research 2005; 33:

The Journal of International Medical Research 2005; 33: The Journal of International Medical Research 2005; 33: 620 631 Ambulatory Blood Pressure Comparison of the Anti-hypertensive Efficacy of Fixed Combinations of Irbesartan/hydrochlorothiazide and Losartan/hydrochlorothiazide

More information

Clinical trials and clinical pharmacology 21. Blood Pressure Monitoring 2008, 13:21 27

Clinical trials and clinical pharmacology 21. Blood Pressure Monitoring 2008, 13:21 27 Clinical trials and clinical pharmacology 21 Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial William B.

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:

More information

BLOOD PRESSURE-LOWERING TREATMENT

BLOOD PRESSURE-LOWERING TREATMENT BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING

More information

Indication as per product monograph: Indicated for the treatment of mild to moderate essential hypertension.

Indication as per product monograph: Indicated for the treatment of mild to moderate essential hypertension. Report on New Patented Drugs Olmetec Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drug products conducted by Board Staff for purposes of applying the

More information

The Road to Renin System Optimization: Renin Inhibitor

The Road to Renin System Optimization: Renin Inhibitor The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension

More information

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy (2006) 20, 169 175 & 2006 Nature Publishing Group All rights reserved 0950-9240/06 $30.00 www.nature.com/jhh REVIEW The importance of early antihypertensive efficacy: the role of angiotensin II receptor

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

Title: Angiotensin II Receptor Blockers: A Comparative Effectiveness Review

Title: Angiotensin II Receptor Blockers: A Comparative Effectiveness Review Title: Angiotensin II Receptor Blockers: A Comparative Effectiveness Review Date: 10 April 2008 Context and policy issues: Angiotensin II receptor blockers (ARB s) are a class of drugs that affect the

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston

AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

The incidence of transient myocardial ischemia,

The incidence of transient myocardial ischemia, AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand

More information

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan Josep Redon, Maria Jose Fabia Key words: angiotensin receptor blocker, blood pressure, hypertension, olmesartan,

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Hypertension is a risk factor for coronary

Hypertension is a risk factor for coronary Original Paper Comparative Efficacy of Two Different b-blockers on 24-Hour Blood Pressure Control Pantelis Sarafidis MD, PhD; 1,2 Zvezdana Bogojevic, MD; 1 Emad Basta, MD; 1 Emily Kirstner, PhD; 3 George

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical

More information

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1

More information

Causes of Poor BP control Rates

Causes of Poor BP control Rates Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

Department of Cardiology, China-Japan Friendship Hospital, Beijing (China) 1

Department of Cardiology, China-Japan Friendship Hospital, Beijing (China) 1 European Review for Medical and Pharmacological Sciences Reduction of the morning blood pressure surge treated with Olmesartan in Chinese patients with mild to moderate essential hypertension a multicenter,

More information

Modern Management of Hypertension: Where Do We Draw the Line?

Modern Management of Hypertension: Where Do We Draw the Line? Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

Ferrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.

Ferrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular mortality in hypertension: a meta-analysis of randomized controlled trials Ferrari R, Fox K, Bertrand

More information

Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations

Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine

More information

Modern Management of Hypertension

Modern Management of Hypertension Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

The renin-angiotensin-aldosterone system

The renin-angiotensin-aldosterone system Cardiology 59 Using ARBs in the elderly patient Effective management of hypertension can substantially reduce the risk of complications. The angiotensin receptor blockers are one of the latest anti-hypertensive

More information

The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension Focus on Recent Studies

The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension Focus on Recent Studies REVIEW ARTICLE Am J Cardiovasc Drugs 2010; 10 (5): 315-320 1175-3277/10/0005-0315/$49.95/0 ª 2010 Adis Data Information BV. All rights reserved. The Role of Angiotensin Receptor Blocker and Calcium Channel

More information

ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*

ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical

More information

Preventing the cardiovascular complications of hypertension

Preventing the cardiovascular complications of hypertension European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

ORIGINAL ARTICLE. JR Benz 1, HR Black 2, A Graff 3, A Reed 4, S Fitzsimmons 5 and Y Shi 5 1. Introduction

ORIGINAL ARTICLE. JR Benz 1, HR Black 2, A Graff 3, A Reed 4, S Fitzsimmons 5 and Y Shi 5 1. Introduction Journal of Human Hypertension (1998) 12, 861 866 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Valsartan and hydrochlorothiazide in patients

More information

Mayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi

Mayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi 334 Concise Review for Clinicians Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure Concise Review for Clinicians PRERANA MANOHAR, MD, AND ILEANA L. PIÑA, MD Angiotensin

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

EPLERENONE (INSPRA ) THE FIRST SELECTIVE ALDOSTERONE RECEPTOR ANTAGONIST FOR THE TREATMENT OF HYPERTENSION

EPLERENONE (INSPRA ) THE FIRST SELECTIVE ALDOSTERONE RECEPTOR ANTAGONIST FOR THE TREATMENT OF HYPERTENSION Volume 18, Issue 6 March 2003 EPLERENONE (INSPRA ) THE FIRST SELECTIVE ALDOSTERONE RECEPTOR ANTAGONIST FOR THE TREATMENT OF HYPERTENSION Eun-Jeong Kim, Pharm.D. Candidate Introduction Approximately 50

More information

ABSTRACT ORIGINAL RESEARCH. Joel Neutel Ali Shojaee Jen-Fue Maa. Adv Ther (2012) 29(6): DOI /s z

ABSTRACT ORIGINAL RESEARCH. Joel Neutel Ali Shojaee Jen-Fue Maa. Adv Ther (2012) 29(6): DOI /s z Adv Ther (212) 29(6):58 523. DOI 1.17/s12325-12-3-z ORIGINAL RESEARCH Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II

More information

Hypertension: Focus on Olmesartan Medoxomil

Hypertension: Focus on Olmesartan Medoxomil REVIEW Hypertension: Focus on Olmesartan Medoxomil Allison M. Bell 1 and Diane Nykamp 2 1 Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia U.S.A. 2 Department of Pharmacy Practice,

More information

Clinical Trial Synopsis TL-OPI-525, NCT#

Clinical Trial Synopsis TL-OPI-525, NCT# Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

A Placebo-Controlled, Forced Titration Study. Yves Lacourcière and Roland Asmar for the Candesartan/Losartan study investigators

A Placebo-Controlled, Forced Titration Study. Yves Lacourcière and Roland Asmar for the Candesartan/Losartan study investigators AJH 1999;12:1181 1187 A Comparison of the Efficacy and Duration of Action of Candesartan Cilexetil and Losartan as Assessed by Clinic and Ambulatory Blood Pressure After a Missed Dose, in Truly Hypertensive

More information

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,

More information

IJRPC 2011, 1(3) Patel et al. ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY

IJRPC 2011, 1(3) Patel et al. ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article EVALUATION OF COMPLIANCE AND BLOOD PRESSURE REDUCTION IN PATIENTS TREATED WITH AMLODIPINE

More information

New updates on Hypertension and Heart Failure 2015 Yiu Kai Hang

New updates on Hypertension and Heart Failure 2015 Yiu Kai Hang New updates on Hypertension and Heart Failure 2015 Yiu Kai Hang MD, MBBS, MRCP, FHKCP, FHKAM, FRCP (Edin) Clinical Associate Professor Cardiology Division, Department of Medicine, HKU Honorary Consultant,

More information

Don t let the pressure get to you:

Don t let the pressure get to you: Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Managing hypertension: a question of STRATHE

Managing hypertension: a question of STRATHE (2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,

More information

Systolic Hypertension in the Elderly: Addressing an Unmet Need

Systolic Hypertension in the Elderly: Addressing an Unmet Need REVIEW Systolic Hypertension in the Elderly: Addressing an Unmet Need Daniel A. Duprez, MD, PhD Cardiovascular Division, Medical School, University of Minnesota, Minn. ABSTRACT Systolic hypertension is

More information

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park. Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

Large therapeutic studies in elderly patients with hypertension

Large therapeutic studies in elderly patients with hypertension (2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional

More information

Reducing proteinuria

Reducing proteinuria Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors

More information

Phase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018

Phase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018 Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

The control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS

The control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

47 Hypertension in Elderly

47 Hypertension in Elderly 47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary

More information

Original Paper. ID: 7805

Original Paper.   ID: 7805 Original Paper The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Patients With and Without High Cardiovascular Risk Matthew R. Weir, MD; 1

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Don t let the pressure get to you:

Don t let the pressure get to you: Balanced information for better care Don t let the pressure get to you: An update on the changing recommendations for treating hypertension New trial data and guidelines have made hypertension care more

More information

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment

More information

COPYRIGHT JRAAS LIMITED REPRODUCTION PROHIBITED

COPYRIGHT JRAAS LIMITED REPRODUCTION PROHIBITED Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension Joel M Neutel, F Wilford Germino,* David Smith Keywords: Irbesartan, Amlodipine, Ambulatory

More information

Hypertension Management: A Moving Target

Hypertension Management: A Moving Target 9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,

More information

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure

More information

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2 Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic

More information

Morning Hypertension: A Pitfall of Current Hypertensive Management

Morning Hypertension: A Pitfall of Current Hypertensive Management Review Article Hypertension: A Pitfall of Current Hypertensive Management JMAJ 48(5): 234 240, 2005 Kazuomi Kario* 1 Abstract has recently attracted more attention because of the close relation between

More information

In patients with severe hypertension, the shortterm

In patients with severe hypertension, the shortterm Review Paper The Risks and Benefits of Initial Irbesartan Hydrochlorothiazide Combination Therapy in Patients With Severe Hypertension Pablo Lapuerta, MD; 1 * Stanley Franklin, MD 2 The impact of delays

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider

More information

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.

9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008 Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It

More information

ACE inhibitors vs ARBs Myths and Facts

ACE inhibitors vs ARBs Myths and Facts ACE inhibitors vs ARBs Myths and Facts Prof. Dr. med. Frank Ruschitzka, FRCP (Edinburgh) Director Heart Failure/Transplantation Clinic University Clinic Zurich Switzerland Conflict of interest: Bayer,

More information